VJHemOnc is committed to improving our service to you

EHA 2020 | Idecabtagene vicleucel for R/R myeloma

VJHemOnc is committed to improving our service to you

Jesús San Miguel

Jesus San Miguel, MD, of the University of Navarra, Navarra, Spain, updates us on the KarMMa study (NCT03361748), which investigated the BCMA-targeted CAR-T cell therapy, idecabtagene vicleucel, in relapsed or refractory (R/R) multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter